[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
It is not appropriate for everyone, and a full review comes first
In common with ipamorelin, CJC-1295 has yet to pass human clinical trials and is not FDA approved
A variety also helps give different muscle groups time to recover while still building a consistent routine and making long-term progress
188 Maintaining a healthy body weight
128 an important role for SIRT1 in FGF21 expression was also recently demonstrated
